---

Mucormycosis-“The deadly fungal disease” and its prosthodontic management

---

Review Article

Author Details : Rohit Raghavan, Shajahan PA, Shilpa RS*

Volume : 4, Issue : 2, Year : 2022

Article Page : 70-74

https://doi.org/10.18231/j.jdp.2022.014

Suggest article by email

Get Permission

---

Abstract

Coronavirus Disease 2019 (COVID-19), during the second wave in early 2021 has created devastating chaos. Adding more burden to such a challenging situation, mucormycosis an angioinvasive, fulminant fungal infection has seen a sudden surge in patients with COVID -19. Mucormycosis commonly affects immunocompromised patients. Early diagnosis, elimination of the predisposing factor, and surgical debridement, along with antifungal therapy, are the key factors responsible for successful treatment and patient survival. Mucormycosis is presented by various clinical forms. The present paper reviews about the clinical presentation, diagnosis and various treatment modalities for managing mucormycosis-"the deadly fungal disease".
 

Keywords: Mucormycosis, Clinical forms, Antifungal therapy, Prosthodontic Rehabilitation, surgical obturator

How to cite : Raghavan R, Shajahan Pa, Shilpa Rs, Mucormycosis-“The deadly fungal disease” and its prosthodontic management. J Dent Panacea 2022;4(2):70-74

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 International License, which allows others to remix, and build upon the work, the licensor cannot revoke these freedoms as long as you follow the license terms.